1. Scrip
  2. >>New Products

Zeposia’s Ulcerative Colitis Approval Provides BMS’s Beachhead Into GI

 
• By Joseph Haas

The second US approval for the S1P receptor agonist brings Bristol into the gastrointestinal space, and is just the starting point for the pharma in that arena, the company told Scrip.

FDA approved background, 3D rendering, blue street sign
Ulcerative colitis is Zeposia's second US indication

Bristol Myers Squibb Company is moving into a new arena with the US approval of Zeposia (ozanimod) for ulcerative colitis, the company’s first approval in gastrointestinal disease. The company intends this approval – the second for the S1P modulator – to be the first of several in the GI space.

Zeposia, acquired in the $74bn buyout of Celgene Corporation, was initially approved by the US Food and Drug Administration in March 2020 for relapsing forms of multiple sclerosis and was launched in June as BMS took time to determine how best to launch a new therapy in the midst of a pandemic

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.